Consensus ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Delayed Nasdaq Other stock markets 15:59:30 2024-04-29 EDT			5-day change	1st Jan Change
16.93 ^USD	+0.42%		+18.76%	+13.50%

04-18	Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing	MT
04-10	ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept	MT

Evolution of the average Target Price on ALX Oncology Holdings Inc.

Price target over the last 5 years

History of analyst recommendation changes

70763bff8bbb017fa7d3.c7GwH9bwSHbvdWqG3RhjgbfaTontTmNrJkH9IWbdonM.JP_JUbnIKjOrLwj1qGoA0_SCI9C1GxMgdzS8Y1C1z0Q_x91ZtKkdOL0BHQ~ffca5de74189f89b1d61dc61e095e209

Analyst Recommendations on ALX Oncology Holdings Inc.

Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing	04-18	MT
UBS Adjusts ALX Oncology Price Target to $25 From $27, Maintains Buy Rating	03-13	MT
H.C. Wainwright Adjusts Price Target on ALX Oncology to $20 From $17.50, Keeps Buy Rating	03-11	MT
Piper Sandler Adjusts Price Target on ALX Oncology Holdings to $21 From $11, Maintains Overweight Rating	03-08	MT
Stifel Downgrades ALX Oncology Holdings to Hold From Buy, Adjusts Price Target to $14 From $10	03-08	MT
Jefferies Upgrades ALX Oncology to Buy From Hold, Adjusts Price Target to $18 From $8	12-08	MT
Stifel Trims ALX Oncology Holdings' Price Target to $10 From $11, Maintains Buy Rating	11-14	MT
Piper Sandler Raises Price Target on ALX Oncology to $11 From $8, Maintains Overweight Rating	23-10-11	MT
UBS Adjusts ALX Oncology Price Target to $27 From $29, Maintains Buy Rating	23-10-04	MT
Cantor Fitzgerald Raises Price Target on ALX Oncology to $23 From $18, Maintains Overweight Rating	23-10-04	MT
Cantor Fitzgerald Cuts Price Target on ALX Oncology Holdings to $18 From $22, Maintains Overweight Rating	23-08-14	MT
HC Wainwright Adjusts ALX Oncology Price Target to $16 From $30, Maintains Buy Rating	23-08-11	MT
UBS Adjusts ALX Oncology's Price Target to $29 From $31, Maintains Buy Rating	23-03-15	MT
Credit Suisse Lowers ALX Oncology Holdings' Price Target to $34 From $38, Keeps Outperform Rating	23-03-10	MT
HC Wainwright Adjusts ALX Oncology Price Target to $30 From $65, Maintains Buy Rating	23-03-10	MT
HC Wainwright Lowers Price Target on ALX Oncology Holdings to $65 From $80, Maintains Buy Rating	22-11-09	MT
UBS Adjusts ALX Oncology Price Target to $31 From $37, Maintains Buy Rating	22-08-26	MT
Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintains Overweight Rating	22-08-09	MT
Credit Suisse Lowers ALX Oncology Holdings' PT to $38 from $43, Notes Increased Discount Rate to Reflect Greater Uncertainty on Interest Rate/Inflation; Keeps Outperform Rating	22-08-09	MT
Stifel Adjusts Price Target on ALX Oncology Holdings to $16 From $35, Reiterates Buy Rating	22-06-06	MT
Piper Sandler Adjusts Price Target on ALX Oncology Holdings to $48 From $70, Reiterates Overweight Rating	22-05-19	MT
Cantor Fitzgerald Adjusts Price Target for ALX Oncology to $60 From $103, Maintains Overweight Rating	22-03-14	MT
Stifel Adjusts ALX Oncology Holdings' Price Target to $36 from $60, Maintains Buy Rating	22-03-01	MT
HC Wainwright Adjusts Price Target on ALX Oncology Holdings to $80 From $100, Reiterates Buy Rating	22-03-01	MT
Credit Suisse Lowers ALX Oncology Holdings' Price Target to $41 from $53, Maintains Outperform Rating	22-02-14	MT